Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-08-02
2011-08-02
Marx, Irene (Department: 1651)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S283000, C540S478000
Reexamination Certificate
active
07989489
ABSTRACT:
Antitumor combinations comprising a taxane and at least one therapeutically useful substance for treating neoplastic diseases are described.
REFERENCES:
patent: 4206221 (1980-06-01), Miller et al.
patent: 4814470 (1989-03-01), Colin et al.
patent: 4857653 (1989-08-01), Colin et al.
patent: 4876399 (1989-10-01), Holton et al.
patent: 4892735 (1990-01-01), Harrap
patent: 5015744 (1991-05-01), Holton
patent: 5136060 (1992-08-01), Holton
patent: 5229526 (1993-07-01), Holton
patent: 5254580 (1993-10-01), Chen et al.
patent: 5262409 (1993-11-01), Margolis et al.
patent: 5294637 (1994-03-01), Chen et al.
patent: 5294737 (1994-03-01), Ojima
patent: 5466834 (1995-11-01), Holton
patent: 5476954 (1995-12-01), Bourzat et al.
patent: 5494683 (1996-02-01), Liversidge et al.
patent: 5532388 (1996-07-01), Bouchard et al.
patent: 5645988 (1997-07-01), Vande Woude et al.
patent: 5728687 (1998-03-01), Bissery
patent: 5814658 (1998-09-01), Bouchard et al.
patent: 5908835 (1999-06-01), Bissery
patent: 6214863 (2001-04-01), Bissery
patent: 6239167 (2001-05-01), Bissery
patent: 6441026 (2002-08-01), Bissery
patent: 6448030 (2002-09-01), Rust et al.
patent: 6465448 (2002-10-01), Gerson et al.
patent: 6664288 (2003-12-01), Pardee et al.
patent: 317401 (1989-05-01), None
patent: 738 253 (1995-06-01), None
patent: 0 827 745 (1998-03-01), None
patent: 0 827 745 (1998-03-01), None
patent: 0 982 028 (2000-03-01), None
patent: WO 92/09589 (1992-06-01), None
patent: WO 92/19765 (1992-11-01), None
patent: WO 94/10995 (1994-05-01), None
patent: WO 94/13654 (1994-06-01), None
patent: WO 94/13655 (1994-06-01), None
patent: WO 97/38731 (1997-10-01), None
patent: WO 99/31140 (1999-06-01), None
Speicher et al., Cancer Research, vol. 52, Issue 16 4433-4440, 1992.
Baysass et al., Recent results Cancer Research, 1980, vol. 74.pp. 91-97.
Pierre et al., Cancer Research, vol. 51, pp. 2312-2318 1991.
Guéritte-Voegelein et al., “Relationships between the Structure of Taxol Analogues and Their Antimitotic Activity,”J. Med. Chem. 34:992-998 (1991).
Commerçon et al., “Tetrahedron Letters,” 33(36):5185-5188 (1992).
Chen et al., “Serendipitous Synthesis of a Cyclopropane-Containing Taxol Analog Via Anchimeric Participation of an Unactivated Angular Methyl Group,”J. Org. Chem., 58:4520-4521 (1993).
Klein et al., “Synthesis of Ring B-Rearranged Taxane Analogs,”J. Org. Chem., 59: 2370-2373 (1994).
Rowinsky, E., et al., “The Clinical Pharmacology and Use of Antimicrotubule Agents in Cancer Chemotherapeutics,”Pharmac. Ther., vol. 52, pp. 35-84 (1991).
Rowinsky, E. et al., “Sequences of Taxol and Cisplatin: A Phase I and Pharmacologic Study,”J. of Clin. Oncology, vol. 9, No. 9, pp. 1692-1703 (1991).
Bissery, M., et al., Abstract 2645,Proceedings of the AACR, vol. 33, p. 443 (Mar. 1992).
Bissery, M., et al., “Preclinical Profile of Docetaxel (Taxotere): Efficacy as a Single Agent and in Combination,”Seminars in Oncology, vol. 22, No. 6 (Suppl 13), pp. 3-16 (1995).
Bissery, M., et al., Abstract 1599, “Preclinical In Vivo Activity of Docetaxel Containing Combinations,”Proceedings of ASCO, vol. 14, p. 489 (1995).
Bissery, M., et al., “The Taxoids,”Cancer Therapeutics: Experimental and Clinical Agents, Chapter 8, pp. 175-193 (1997).
Mirabelli, C., et al., “A Murine Model to Evaluate the Ability of In Vitro Clonogenic Assays to Predict the Response to Tumors In Vivo,”Cancer Res., vol. 48, pp. 5447-5454 (1988).
Llombart-Cussac, A., et al.,Proceedings of ASCO, vol. 16 (1997), Abstract No. 629.
Gelmon, K., et al., “Phase I Dose-Finding Study of a New Taxane, RPR 109881A, Administered as a One-Hour Intravenous Infusion Days 1 and 8 to Patients with Advanced Solid Tumors,”Journal of Clin. Oncology, vol. 18, No. 24, pp. 4098-4108 (2000).
Kurata, T., et al., “Phase I and Pharmacokinetic Study of a New Taxoid, RPR 109881A, Given as a 1-Hour Intravenous Infusion to Patients with Advanced Solid Tumors,”Journal of Clin. Oncology, vol. 18, No. 17, pp. 3164-3171 (2000).
Budavari, S., et al., “Docetaxel,” “The Merck Index, 13th Edition,”Merck Research Laboratories, 3431, pp. 597-598, “Paclitaxel”, p. 1251 (Ed. 2001).
Hartley-Asp, B., “Estramustine-Induced Mitotic Arrest in Two Human Prostatic Carcinoma Cell Lines DU 145 and PC-3,”The Prostate, vol. 5, pp. 93-100 (1984).
Horwitz, S., et al., “Taxol: A New Probe for Studying the Structure and Function of Microtubes,”Cold Spring Harbor Symposia on Quantitative Biology, Organization of the Citoplasm, vol. XLVI, pp. 219-226 (1982).
Bissery et al., “Experimental Antitumor Activity of Taxotere (RP 56976, NSC 628503), a Taxol Analogue,” Cancer Res. Sep. 15, 1991;51(18):4845-52.
Bissery et al., “Docetaxel (Taxotere): A Review of Preclinical and Clinical Experience. Part I: Preclinical experience,” Anticancer Drugs. Jun. 1995;6(3):339-55, 363-8.
Bissery et al., “Preclinical Profile of Docetaxel (Taxotere): Efficacy As a Single Agent and in Combination,” Semin Oncol. Dec. 1995:22(6 Suppl 13):3-16.
Corbett et al., “Response of Transplantable Tumors of Mice to Anthracenedione Derivatives Alone and in Combination with Clinically Useful Agents,” Cancer Treat Rep. May 1982:66(5)1187-200.
Corbett et al., “5-Fluorouracil Containing Combinations in Murine Tumor Systems,” Invest New Drugs. Apr. 1989;7(1):37-49.
Harrison et al., “Evaluation of Combinations of Interferons and Cytotoxic Drugs in Murine Tumor Models in Vivo,” J Biol Response Mod. Aug. 1990;9(4):395.400.
Lorusso et al., “Antitumor Efficacy of Interleukin-2 Alone and in Combination with Adriamycin and Dacarbazine in Murine Solid Tumor Systems,” Cancer Res. Sep. 15, 1990;50(18):5876-82.
Burris, H.A., et al.; “Phase II trial of docetaxel and Herceptin (R) as first- or second-line chemotherapy for women with metastatic breast cancer whose tumors overexpress HER2;”European Journal of Cancer, Sep. 16, 1999; 35(suppl. 4):S322; Abstract 1293.
Baselga, J., et al.; “Recombinant Humanized Anti-HER2 Antibody (Herceptin™) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2
euOverexpressing Human Breast Cancer Xenografts;”Cancer Research; Jul. 1, 1998; 58:2825-2831.
Baselga, J., et al.; “Erratum;”Cancer Research; Apr. 15, 1999; 59(8):2020-2021.
Baselga, J., et al.; “HER2 Overexpression and Paclitaxel Sensitivity in Breast Cancer: Therapeutic Implications.,”Oncology; Mar. 1997; 11(3)(suppl. 2):43-48.
Cobleigh, M.A., et al.; “Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease;”J. Clin. Oncol.; Sep. 1999; 17(9):2639-2648.
Gianni, L., et al.; “Putting Taxanes to Work in Operable Breast Cancer: A Search for Selective Indications from Empirical Studies:”Recent Results Cancer Research; 1998; 152:314-322.
Vogel, C.L., et al.; “Monotherapy of Metastatic Breast cancer: A Review of Newer Agents:”The Oncologist; 1999; 4:17-33.
“Are adjuvant Herceptin trials using the wrong drugs?;”Scripp; Nov. 26, 1999; 2493:21.
Corbett, T.H., et al.; “Design and Evaluation of Combination Chemotherapy Trials in Experimental Animal Tumor Systems:”Cancer Treatment Reports; May 1997; 63(5):799-801.
Munkrah A., et al.; “Comparative Studies of Taxol and Taxotere on Tumor Growth and Lymphocyte Functions;”Gynecologic Oncology, 1994; 55:211-216.
Lopes, N.M., et al.; “Assessment of microtubule stabilizers by semiautomated in vitro microtubule protein polymerization and mitotic block assays;”Cancer Chemother. Pharmacol.; 1997; 41:37-47.
Johnson, R.A.; “Taxol Chemistry. 7-O-Triflates as Precursors to Olefins and Cyclopropane
Aventis Pharma S.A.
Finnegan Henderson Farabow Garrett & Dunner LLP
Marx Irene
LandOfFree
Method of treating leukemia with docetaxel and vinca alkaloids does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating leukemia with docetaxel and vinca alkaloids, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating leukemia with docetaxel and vinca alkaloids will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2666883